N O., E K., D D., G O., Serilmez M., Ho S., ...Daha Fazla
MITTEILUNGEN KLOSTERNEUBURG, sa.Vol. 40 (n. 2, 2025), ss.4-13, 2025 (Scopus)
-
Yayın Türü:
Makale / Tam Makale
-
Basım Tarihi:
2025
-
Doi Numarası:
10.61586/b41ec
-
Dergi Adı:
MITTEILUNGEN KLOSTERNEUBURG
-
Derginin Tarandığı İndeksler:
Scopus, BIOSIS, CAB Abstracts
-
Sayfa Sayıları:
ss.4-13
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Purpose: Breast cancer is the most prevalent form of cancer among women worldwide, and
is a complex disease. The development of biomarkers for early diagnosis is a promising avenue for
improving the treatment of breast cancer. Doublecortin-like kinase 1 (DCLK1) is a member of the
protein kinase superfamily and doublecortin family. It has been hypothesised that cells expressing
DCLK1 in these tumours exhibit stem cell characteristics, suggesting a potential association with
tumour initiation and mortality. The objective of this study was to evaluate the serum protein and
mRNA levels of the DCLK1 molecule in patients diagnosed with breast cancer.
Methods: The present study comprised 62 female patients diagnosed with breast cancer and
30 healthy controls. DCLK1 serum level was determined by ELISA, and mRNA level was
determined by quantitative RT-PCR method before any treatment.
Results: Serum DCLK1 level was found to be statistically significantly lower in breast
cancer patients (5.38 ± 1.86 ng/mL) than in the control group (7.5 ± 1.15 ng/mL) (p = 0.001).
Furthermore, we determined that serum DCLK mRNA expression level was significantly lower in
breast cancer patients (0.012-0.09, mean rank: 34.48) compared to the control group (0.04-0.09,
mean rank: 61.22) (p <0.001, Z: -4.29).
Conclusion: DCLK1 may be a useful marker for detection of the clinical behaviour of
breast cancer.